Despite LifeMD's robust revenue growth and optimistic foreca...

Despite LifeMD's robust revenue growth and optimistic forecasts, its P/S ratio aligns with the industry, hinting at shareholder skepticism. If analyst predictions hold true, the stock may be undervalued at present.